Related Experiment Video
Updated: Feb 5, 2026
12:24
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
Published on: June 3, 2014
12.7K
Pharmacodynamic Interaction Between Emicizumab and Coagulation Factor VIII
Matthias Chill1, Emma Louise Konarski1, Annika Klingberg1
1Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Thrombosis and Haemostasis
|February 3, 2026
Summary
Emicizumab and Factor VIII (FVIII) show a synergistic effect, enhancing blood clotting at low FVIII concentrations. This interaction, crucial for hemostasis, diminishes as FVIII levels increase beyond 20 IU/dl.
Area of Science:
- Hematology
- Pharmacology
- Biochemistry
Background:
- Emicizumab, a bispecific antibody, mimics activated Factor VIIIa (FVIIIa) to aid Factor IXa in activating Factor X.
- Emicizumab's lower affinity for FIX/IXa and FX compared to FVIIIa suggests FVIII might displace it at higher concentrations.
- The interaction between emicizumab and FVIII at low concentrations remains poorly understood.
Purpose of the Study:
- To investigate the pharmacodynamic interaction between emicizumab and FVIII.
- To evaluate additivity and synergy between emicizumab and FVIII using thrombin generation as a marker.
Main Methods:
- Tissue factor-triggered thrombin generation assays were performed.
- FVIII-deficient plasma was supplemented with varying concentrations of emicizumab and recombinant FVIII, alone and in combination.
- Thrombin generation served as a quantitative measure of hemostatic capacity.
Main Results:
- A synergistic interaction was observed between emicizumab and FVIII.
- This synergy significantly enhanced endogenous thrombin potential and peak thrombin generation.
- The synergistic effect was prominent at low FVIII concentrations (below 20 IU/dl) and disappeared at higher levels.
Conclusions:
- Emicizumab and FVIII exhibit synergy, explaining emicizumab's efficacy at low FVIII levels.
- This interaction provides a framework for assessing novel non-factor therapies with intrinsic FVIII.
- Pharmacodynamic synergy is key to understanding emicizumab's hemostatic effects in specific patient populations.
Related Concept Videos
01:06Coagulation
1.4K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.4K
01:09Coagulation
10.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
10.5K
01:21Pharmacodynamics: Overview and Principles
3.3K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
3.3K
01:20Measurement of Bioavailability: Pharmacodynamic Methods
772
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
772
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
605
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
605
02:16Transcription Factors
82.8K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
82.8K